Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B

New Microbiologica

Volumn 28, Issue 3, 2005, Pages 193-197

  Scotto, Gaetano ^a   Palumbo, Emilio ^a   Fazio, Vincenzina ^b   Tartaglia, Alessandra ^a   Saracino, Annalisa ^a   Angarano, Gioacchino ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Hospital of Foggia   (Italy)

Author keywords

Adefovir; HBeAg negative; Hepatitis B; Resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ADENINE; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; CLINICAL TRIAL; FEMALE; HEPATITIS B; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VIREMIA; VIROLOGY;

ADENINE; ADMINISTRATION, ORAL; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; VIREMIA;

HEPATITIS B VIRUS;

EID: 25444511348     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. ALLEN, M.I., DESLAURIERS, M., ANDREWS, C.W., TIPPLES, G.A., WALTERS, K.A., TYRRELL, D.L., BROWN N., CONDREAY, L.D. (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 27, (6): 1670-1677.
2. BENHAMOU, Y., BOCHET, M., THIBAULT, V., CALVEZ, V., FIEVET, M.H., VIG, P., GIBBS, C.S., BROSGART, C., FRY, J., NAMINI, H., KATLAMA, C., POYNARD, T. (2001). Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet, 358, (9283): 718-723.
3. BRUNETTO, M.R., OLIVIERI, F., ROCCA, G., CRISCUOLO, D., CHIABERGE, E., CAPALBO, M., DAVID, E., VERME, G., BONINO, F. (1989). Natural course and response to Interferon of chronic hepatitis B accompanied by antibodies to hepatitis e antigen. Hepatology, 10, 198-202.
4. BUTI, M., COTRINA, M., JARDI, R., DE CASTRO, E.C., RODRIGUEZ-FRIAS, F., SANCHEZ-AVILA, F., ESTEBAN, R., GUARDIA, J. (2001). Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat, 8, (4): 270-275.
5. CHU, C.M., LIAU, Y.F. (1997). Natural history of chronic B virus infection: an immunopathological study. J Gastroenterol Hepatol, 12, S218-S222.
6. DANTA, M., DUSHEIKO, G. (2004). Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. Int J Clin Pract, 58, (9): 877-887.
7. HADZIYANNIS, S.J., TASSOPOULOS, N.C., HEATHCOTE, E.J., CHANG, T.T., KITIS, G., RIZZETTO, M., MARCELLIN, P., LIM, S.G., GOODMAN, Z., WULFSOHN, M.S., XIONG, S., FRY, J., BROSGART, C.L. for the Adefovir Dipivoxil 438 Study Group (2003). Adefovir Dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 348, 800-8007.
8. ISHAK, K.G., BAPTISTA, A., BIANCHI, L., CALLEA, F., DE GROOTE, J., GUDAT, F., DENK, H., DESMET, V., KORB, G., MACSWEEN, R.T. (1995). Histological grading and stading of chronic hepatitis. J Hepatology, 22, 696-696.
9. KNODELL, R.G., ISHAK, K.G., BLACK, W.C., CHEN, T.S., CRAIG, R., KAPLOWITZ, N., KIERNAN, T.W., WOLLMAN, J. (1981). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1, 431-35.
10. LAI, C.L., LIAW, Y.F. (1997). Lamivudine therapy for chronic hepatitis B infection: a 12 months placebo-controlled, double-blind, multicentre study. J Hepatol, 3, (22) P/CO 1/19:81.
11. LAI, C.J., TERRAULT, N.A. (2004). Antiviral therapy in patients with chronic hepatitis B and chirrosis. Gastroenterol Clin North Am, 33, (3):629-54.
12. LAU, D.T., KHOKHAR, M.F., DOO, E., GHANY, M.G., HERION, D., PARK, Y., KLEINER, D.E., SCHMID. P., CONDREAY, L.D., GAUTHIER, J., KUHNS, M.C., LIANG, T.J., HOOFNAGLE, J.H. (2000). Long-term therapy of chronic hepatitis B with lamivudine. Hepatology, 32: 828-34.
13. LOK, A.S.F., MCMAHON, B.J. (2001). Chronic hepatitis B. Hepatology, 34, 1225-41.
14. OLIVIERI, F., SANTANTONIO, T., BELLATI, G., COLOMBATTO, P., MELS, G.C., CARRIERA, L., DATOLI, G., PASTORE, G., IDEO, G., BONINO, F., BRUNETTO, M.R. (1999). Long-term response to therapy of chronic anti-HBe positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol, 94, 1366-1372.
15. PASTORE, G., SANTANTONIO, T., MICELLA, M., IACOVAZZI, T., LONGO, A., PIETRAMATERA, G. (1995). Interferon treatment in chronic hepatitis B. Minerva Gastroenterol Dietol, 41, (1): 97-102.
16. PERRILLO, R., SCHIFF, E., YOSHIDA, E., STATLER, A., HIRSCH, K., WRIGHT, T., GUTFREUD, K., LAMY, P., MURRAY, A. (2000). Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 32, (1): 129-134.
17. QAQISH, R.B., MATTES, K.A., RITCHIE, D.J. (2003). Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther, 25, (12): 3084-99.
18. RENAULT, P.F., HOOFNAGLE, J.M. (1989). Side effects of alpha interferon. Sem Liver Dis, 9, 273-277.
19. SCOTTO, G., FAZIO, V., CAMPANOZZI, F., D'ADDUZIO, A. (2000). Efficacy of treatment with lamivudine in patients with chronic active e-minus variant hepatitis B virus infection: a non-randomized, open label study. Curr Ther Res, 62, 321-330.
20. XIONG, X., FLORES, C., YANG, H., TOOLE, J.J., GIBBS, C.S. (1998). Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology, 28, 1669-1673.
21. YANG, H., WESTLAND, C.E., DELANEY, W.E., HEATHCOTE, E.J., HO, V., FRY, J., BROSGART, C., GIBBS, C.S, MILLER, M.D., XIONG, S. (2002). Resistance surveillance in chronic hepatits B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology, 36, (2): 464-73.